- Home
- HBNC vs ANAB Comparison
HBNC vs ANAB Comparison
Compare HBNC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBNC
- ANAB
- Stock Information
- Founded
- HBNC 1873
- ANAB 2005
- Country
- HBNC United States
- ANAB United States
- Employees
- HBNC N/A
- ANAB N/A
- Industry
- HBNC Major Banks
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- HBNC Finance
- ANAB Health Care
- Exchange
- HBNC Nasdaq
- ANAB Nasdaq
- Market Cap
- HBNC 648.7M
- ANAB 600.4M
- IPO Year
- HBNC N/A
- ANAB 2017
- Fundamental
- Price
- HBNC $18.29
- ANAB $19.22
- Analyst Decision
- HBNC Hold
- ANAB Buy
- Analyst Count
- HBNC 3
- ANAB 11
- Target Price
- HBNC $15.33
- ANAB $54.64
- AVG Volume (30 Days)
- HBNC 173.4K
- ANAB 622.4K
- Earning Date
- HBNC 10-23-2024
- ANAB 11-05-2024
- Dividend Yield
- HBNC 3.50%
- ANAB N/A
- EPS Growth
- HBNC N/A
- ANAB N/A
- EPS
- HBNC 0.48
- ANAB N/A
- Revenue
- HBNC $183,718,000.00
- ANAB $57,172,000.00
- Revenue This Year
- HBNC N/A
- ANAB $207.49
- Revenue Next Year
- HBNC $13.00
- ANAB N/A
- P/E Ratio
- HBNC $37.83
- ANAB N/A
- Revenue Growth
- HBNC N/A
- ANAB 282.17
- 52 Week Low
- HBNC $10.65
- ANAB $13.36
- 52 Week High
- HBNC $18.86
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- HBNC 69.60
- ANAB 27.42
- Support Level
- HBNC $18.30
- ANAB $20.81
- Resistance Level
- HBNC $18.86
- ANAB $22.94
- Average True Range (ATR)
- HBNC 0.49
- ANAB 1.58
- MACD
- HBNC 0.19
- ANAB -0.18
- Stochastic Oscillator
- HBNC 91.11
- ANAB 5.58
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).